The blocking activity of birch pollen-specific immunotherapy-induced IgG4 is not qualitatively superior to that of other IgG subclasses

被引:23
作者
Ejrnaes, AM
Bodtger, U
Larsen, JN
Svenson, M
机构
[1] Univ Copenhagen, Natl Hosp, Inst Inflammat Res, DK-2100 Copenhagen, Denmark
[2] Dept Biol Res, ALK Abello, DK-2970 Horsholm, Denmark
[3] Univ Copenhagen, Natl Hosp, Allergy Clin 7551, DK-2100 Copenhagen, Denmark
关键词
allergy; immunotherapy; blocking antibodies; IgE;
D O I
10.1016/j.molimm.2004.04.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Allergen-specific IgG antibodies induced by specific immunotherapy (SIT) interfere with the allergen-IoE interaction, and act as blocking antibodies in vitro. It has been hypothesised that IgG4, as opposed to other IgG subclasses, is particularly important in this function, which may play a role for the clinical efficacy of SIT. In this study, fractionated serum samples from 14 SIT-treated birch pollen allergic individuals enabled determination of the inhibitory capacity of IgG4 alone versus non-IgG4 IgG. Allergen-binding activities of IaG and the IgG-mediated inhibition of allergen binding to I-labelled rBet v 1.2801, a recombinant variant of the major allergen of Betula verrucosa pollen. autologus IgE were detected using 125 Results show that IgG4-depletion resulted in equivalent reductions in binding and blocking activities. In contrast, a significant but less than two-fold higher relative blocking activity was found in the purified IgG4 fraction. There was no significant difference in the binding avidities (1/K-d) measured in the two IgG fractions. Thus, it appears that SIT-induced specific IgG4 contributes to the I-G blocking of allergen binding to IgE in a simple quantitative manner and not by a particular intrinsic blocking activity. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:471 / 478
页数:8
相关论文
共 50 条
[1]   IgG4 breaking the rules [J].
Aalberse, RC ;
Schuurman, J .
IMMUNOLOGY, 2002, 105 (01) :9-19
[2]  
AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289
[3]  
ADKINSON NF, 1979, J IMMUNOL, V122, P965
[4]   Interleukin-10, T regulatory cells and specific allergy treatment [J].
Blaser, K ;
Akdis, CA .
CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (03) :328-331
[5]   The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study [J].
Bodtger, U ;
Poulsen, LK ;
Jacobi, HH ;
Malling, HJ .
ALLERGY, 2002, 57 (04) :297-305
[6]   Allergen immunotherapy:: therapeutic vaccines for allergic diseases [J].
Bousquet, J ;
Lockey, R ;
Malling, HJ ;
Alvarez-Cuesta, E ;
Canonica, GW ;
Chapman, MD ;
Creticos, PJ ;
Dayer, JM ;
Durham, SR ;
Demoly, P ;
Goldstein, RJ ;
Ishikawa, T ;
Ito, K ;
Kraft, D ;
Lambert, PH ;
Lowenstein, H ;
Müller, U ;
Norman, PS ;
Reisman, RE ;
Valenta, R ;
Valovirta, E ;
Yssel, H .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 81 (05) :401-405
[7]   TGF-β receptor controls B cell responsiveness and induction of IgA in vivo [J].
Cazac, BB ;
Roes, J .
IMMUNITY, 2000, 13 (04) :443-451
[8]   Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever) [J].
Cooke, RA ;
Barnard, JH ;
Hebald, S ;
Stull, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1935, 62 (06) :733-U1
[9]   Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1.: Anti-allergen IgG can enhance the anaphylactic reaction [J].
Denépoux, S ;
Eibensteiner, PB ;
Steinberger, P ;
Vrtala, S ;
Visco, V ;
Weyer, A ;
Kraft, D ;
Banchereau, J ;
Valenta, R ;
Lebecque, S .
FEBS LETTERS, 2000, 465 (01) :39-46
[10]   SERIAL STUDIES ON THE FUNCTIONAL AFFINITY AND HETEROGENEITY OF ANTIBODIES OF DIFFERENT IGG SUBCLASSES TO PHOSPHOLIPASE-A2 PRODUCED IN RESPONSE TO BEE-VENOM IMMUNOTHERAPY [J].
DEVEY, ME ;
LEE, SR ;
RICHARDS, D ;
KEMENY, DM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1989, 84 (03) :326-330